公开(公告)号：US10660888B2

公开(公告)日：2020-05-26

申请号：US16210968

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Jeffrey T. Bagdanoff ,  Yu Ding ,  Wooseok Han ,  Zilin Huang ,  Qun Jiang ,  Xianming Jin ,  Xiang Kou ,  Patrick Lee ,  Mika Lindvall ,  Zhongcheng Min ,  Yue Pan ,  Sabina Pecchi ,  Keith Bruce Pfister ,  Daniel Poon ,  Vivek Rauniyar ,  Xiaojing Michael Wang ,  Qiong Zhang ,  Jianguang Zhou ,  Shejin Zhu

IPC: A61K31/497 ,  C07D213/73 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  C07D241/20 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/5355

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

公开(公告)号：US20220089597A1

公开(公告)日：2022-03-24

申请号：US17191082

申请日：2021-03-03

Applicant: NOVARTIS AG

Inventor： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4523 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20210309663A1

公开(公告)日：2021-10-07

申请号：US17191139

申请日：2021-03-03

Applicant: NOVARTIS AG

Inventor： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4523 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US10975080B2

公开(公告)日：2021-04-13

申请号：US15736959

申请日：2016-06-15

Applicant: NOVARTIS AG

Inventor： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4523 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20190185475A1

公开(公告)日：2019-06-20

申请号：US15736959

申请日：2016-06-15

Applicant: NOVARTIS AG

Inventor： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC: C07D487/04 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US10188649B2

公开(公告)日：2019-01-29

申请号：US15672568

申请日：2017-08-09

Applicant: Novartis AG

Inventor： Jeffrey T. Bagdanoff ,  Yu Ding ,  Wooseok Han ,  Zilin Huang ,  Qun Jiang ,  Xianming Jin ,  Xiang Kou ,  Patrick Lee ,  Mika Lindvall ,  Zhongcheng Min ,  Yue Pan ,  Sabina Pecchi ,  Keith Bruce Pfister ,  Daniel Poon ,  Vivek Rauniyar ,  Xiaojing Michael Wang ,  Qiong Zhang ,  Jianguang Zhou ,  Shejin Zhu

IPC: C07D241/20 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04 ,  C07D213/73 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/5355

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.